Schnupp v. Blair Pharmacy, Inc.

District Court, D. Maryland·Decided June 6, 2024·No. 1:17-cv-02335·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

UNITED STATES ex rel. TIMOTHY SCHNUPP, Relator,

v. Civil No. ELH-17-2335

BLAIR PHARMACY, et al., Defendants.

MEMORANDUM OPINION In this qui tam action, Timothy Schnupp, the Relator, has sued his former employer, Blair Pharmacy, Inc. (“BPI,” “Blair Pharmacy,” or “Pharmacy”), and its director and principal, Matthew Blair (“Mr. Blair”) (collectively, “Blair”), pursuant to the False Claims Act (“FCA” or “Act”), 31 U.S.C. §§ 3728 et seq. See ECF 1 (“False Claims Act Complaint”). In May 2022, following a lengthy investigation, the United States declined to intervene in this case. ECF 28. The Complaint was then unsealed (ECF 29) and, on May 11, 2022, plaintiff filed his “First Amended False Claims Act Complaint.” ECF 30 (the “Amended Complaint”). The Amended Complaint contains two counts. Count I asserts false claims under 31 U.S.C. § 3729(a)(1)(A) and Count II asserts false claims under 31 U.S.C. § 3729(a)(1)(B). Some sixteen months later, on September 13, 2023, Schnupp filed a “Motion for Leave to Supplement the First Amended Complaint.” ECF 113 (the “Motion”). He seeks to add a third claim, alleging unlawful retaliation under 31 U.S.C. § 3730(h). In support of the Motion, plaintiff filed three exhibits. ECF 113-1 to ECF 113-3. These include a copy of a complaint filed in August 2022 by Mr. Blair and Blair Pharmacy in the Circuit Court for Baltimore County, naming as defendants Schnupp and Pharma Resolutions, LLC (“Pharma”), Schnupp’s wholly owned single-member limited liability company (ECF 113-1). In addition, plaintiff filed the proposed Supplemental First Amended False Claims Act Complaint (ECF 113-2) and a redline version of the Supplemental First Amended False Claims Act Complaint (ECF 113-3). Defendants oppose the Motion. ECF 116 (the “Opposition”). And, defendants submitted

three exhibits. ECF 116-1 to ECF 116-3. These include the motion to dismiss the State case, dated October 13, 2022 (ECF 116-1); a copy of Blair’s opposition to that motion, dated November 4, 2022 (ECF 116-2); and a copy of the transcript of the hearing held on January 31, 2023, before Judge Michael S. Barranco of the Circuit Court for Baltimore County (ECF 116-3). No reply was filed, and the time to do so has expired. See Docket. No hearing is necessary to resolve the Motion. See Local Rule 105.6. For the reasons that follow, I shall deny the Motion. I. Factual and Procedural Background Plaintiff filed the qui tam suit in 2017. ECF 1. As noted, the government investigated the

case and, in May 2022, the government declined to intervene. ECF 28. The Complaint was then unsealed. ECF 29. And, the suit was amended. ECF 30. Schnupp alleges, inter alia, that defendants knowingly submitted false claims to the Medicare Program, 42 U.S.C. § 1395 et seq. (“Medicare”), a federally funded health insurance program for people ages 65 and older and for certain people with disabilities (id. ¶¶ 11 et seq.), and to the Department of Defense TRICARE health insurance program. Id. ¶¶ 20 et seq.1 According to the Relator, defendants knowingly submitted false claims to Medicare and TRICARE

1 TRICARE was formerly known as the Civilian Health and Medical Program of the Uniformed Services (“CHAMPUS”). See 32 C.F.R. § 199.17. for certain compound drugs, by substituting a less expensive drug for a more expensive drug; by billing for medication that was not provided; by overcharging for certain medications; and by committing violations of the Anti-Kickback Statute (“AKS”), 42 U.S.C. § 13209-7b(b). See id. ¶¶ 28–43. The claims lodged by the Relator were the subject of a federal criminal prosecution of Mr.

Blair. See United States v. Matthew Blair, ELH-19-410 (D. Md.). Pursuant to a Plea Agreement (id., ECF 181, ECF 181-1), Mr. Blair entered a plea of guilty on December 3, 2021 (id., ECF 178), to Count 31 of the Superseding Indictment (id., ECF 20). That count charged Mr. Blair with Payment of Illegal Remunerations, in violation of 42 U.S.C. § 1320a-7b(b)(2)(A). The Plea Agreement included a lengthy “Stipulation of Facts.” See id., ECF 181-1. And, on February 10, 2022 (id., ECF 188), pursuant to Fed. R. Crim. P. 11(c)(1)(C), Mr. Blair was sentenced to twelve months and one day of imprisonment. See id., ECF 189 (Judgment). In the FCA case, Blair moved to dismiss on June 18, 2022. ECF 38. After briefing (ECF 47, ECF 50), which included several extensions requested by the parties (ECF 42, ECF 43, ECF

48, ECF 49), the Court denied the motion by Memorandum Opinion and Order of December 9, 2022. ECF 55, ECF 56. In the interim, on August 17, 2022, Mr. Blair and BPI filed a civil lawsuit against Schnupp and Pharma in the Circuit Court for Baltimore County. See Blair, et al. v. Schnupp, et al., Case No. C-03-CV-22-003286 (“State Case”); see also ECF 113 at 1, ¶ 3; ECF 116 at 2 n.1.2 In the

2 “A court may properly take judicial notice of ‘matters of public record’ and other information that, under Federal Rule of Evidence 201, constitute ‘adjudicative facts.’” Goldfarb v. Mayor & City Council of Balt., 791 F.3d 500, 508 (4th Cir. 2015); see also Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308, 322 (2007); Katyle v. Penn Nat’l Gaming, Inc., 637 F.3d 462, 466 (4th Cir. 2011), cert. denied, 565 U.S. 825 (2011); Philips v. Pitt Cnty. Mem’l Hosp., 572 F.3d 176, 180 (4th Cir. 2009). This includes taking judicial notice of documents from state court proceedings and other matters of public record, without converting the motion to one for summary State Case, Blair asserted five claims against Schnupp: Breach of Contract (Count I); Intentional Misrepresentation/Fraud (Count II); Fraudulent Concealment (Count III); Negligent Misrepresentation (Count IV); and Breach of Fiduciary Duties (Count V). ECF 113-1, ¶¶ 78–113. And, Blair asserted two claims against both Schnupp and Pharma: Unfair Competition/Trade Secret Misappropriation (Count VI) and Tortious Interference with Economic Relations and/or

Business Relationships (Count VII). Id. ¶¶ 114–27. On October 13, 2022, Schnupp and Pharma moved to dismiss the State Case. ECF 116-1. Relevant here, they argued, in part, id. at 9: “Plaintiffs attempt to bring this lawsuit in retaliation for the federal qui tam action filed by Mr. Schnupp against the Plaintiffs on August 15, 2017, and for the resulting federal criminal prosecution and conviction of plaintiff Matthew Blair.” And, they asserted that the False Claims Act “prohibits retaliation for acts done in furtherance of an FCA lawsuit. See 31 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Schnupp v. Blair Pharmacy, Inc., (D. Md. 2024).

Schnupp v. Blair Pharmacy, Inc. (Schnupp v. Blair Pharmacy, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Equal Rights Center v. NILES BOLTON ASSOCIATES
602 F.3d 597 (Fourth Circuit, 2010)
Foman v. Davis
371 U.S. 178 (Supreme Court, 1962)
Tellabs, Inc. v. Makor Issues & Rights, Ltd.
551 U.S. 308 (Supreme Court, 2007)
KRUPSKI v. COSTA CROCIERE S. P. A
560 U.S. 538 (Supreme Court, 2010)
Tower Ventures, Inc. v. City of Westfield
296 F.3d 43 (First Circuit, 2002)
O'Connell v. Hyatt Hotels
357 F.3d 152 (First Circuit, 2004)
Katyle v. Penn National Gaming, Inc.
637 F.3d 462 (Fourth Circuit, 2011)
Hoyle v. FREIGHTLINER, LLC
650 F.3d 321 (Fourth Circuit, 2011)
Charles T. Coral v. Gavino Gonse
330 F.2d 997 (Fourth Circuit, 1964)
Edwards v. City of Goldsboro
178 F.3d 231 (Fourth Circuit, 1999)
Dennis Glynn v. EDO Corporation
710 F.3d 209 (Fourth Circuit, 2013)
United States Ex Rel. Brooks v. Lockheed Martin Corp.
237 F. App'x 802 (Fourth Circuit, 2007)
Darveau v. Detecon, Inc.
515 F.3d 334 (Fourth Circuit, 2008)
Philips v. Pitt County Memorial Hospital
572 F.3d 176 (Fourth Circuit, 2009)
Galustian v. Peter
591 F.3d 724 (Fourth Circuit, 2010)
Luanna Scott v. Family Dollar Stores, Inc.
733 F.3d 105 (Fourth Circuit, 2013)